Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling pathways

• Published in: Phytomedicine (Stuttgart) Vol. 98; p. 153932
• Main Authors: Yu, Yun, Chen, Didi, Wu, Tao, Lin, Haizhen, Ni, Lianli, Sui, Hehuan, Xiao, Sisi, Wang, Canwei, Jiang, Suping, Pan, Huanle, Li, Shaotang, Jin, Xiance, Xie, Congying, Cui, Ri
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.04.2022
• Subjects: Colorectal cancer; Dihydroartemisinin; Oxaliplatin; Peroxiredoxin 2; ROS; Dihydroartemisinin; DAB; IHC; JNK; Colorectal cancer; STAT3; H&E staining; MTT; eIF2α; DCFH-DA; NAC; PRDX2; SDS-PAGE; Oxaliplatin; Peroxiredoxin 2; CRC; NATs; ROS; PI; DHA; ATF4
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2022.153932

Globally, colorectal cancer (CRC) is one of the leading causes of cancer-related deaths. Oxaliplatin based treatments are frequently used as chemotherapeutic methods for CRC, however, associated side effects and drug resistance often limit their clinical application. Dihydroartemisinin (DHA) induces apoptosis in various cancer cells by increasing reactive oxygen species (ROS) production. However, the direct target of DHA and underlying molecular mechanisms in oxaliplatin-mediated anti-tumor activities against CRC are unclear. We used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), flow cytometry, and colony formation assays to investigate cell phenotype alterations and ROS generation. We also used quantitative Real-Time PCR (qRT-PCR) and western blotting to measure relative gene and protein expression. Finally, an in vivo mouse xenograft model was used to assess the anti-tumor activity of oxaliplatin and DHA alone, and combinations. DHA synergistically enhanced the anti-tumor activity of oxaliplatin in colon cancer cells by regulating ROS-mediated ER stress, signal transducer and activator of transcription 3 (STAT3), C-Jun-amino-terminal kinase (JNK), and p38 signaling pathways. Mechanistically, DHA increased ROS levels by inhibiting peroxiredoxin 2 (PRDX2) expression, and PRDX2 knockdown sensitized DHA-mediated cell growth inhibition and ROS production in CRC cells. A mouse xenograft model showed strong anti-tumor effects from combination treatments when compared with single agents. We demonstrated an improved therapeutic strategy for CRC patients by combining DHA and oxaliplatin treatments. [Display omitted]